Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | EVP, General Counsel | September 04, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sarepta Therapeutics, Inc.
Report date September 04, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 115,519 |
Reported balance
After 2026-09-04 transaction · row 1
1 source rowRow 1 · 2026-09-04 · Tax withholding · Disposed 22,025 · Balance 115,519 F1: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 9, 2026 00:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 22,025 | $22.22 | $489,395.50 |
DisclosureSEC source: 0001193125-26-385541 · ownership.xml · nonDerivative · entry 1 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,519 F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 00:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 974 | $17.03 | $16,587.22 |
DisclosureSEC source: 0001193125-26-106697 · ownership.xml · nonDerivative · entry 1 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,544 F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 10, 2025. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 00:07 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 346 | $16.95 | $5,864.70 |
DisclosureSEC source: 0001193125-26-102708 · ownership.xml · nonDerivative · entry 2 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,518 F2 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 00:07 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 484 | $16.95 | $8,203.80 |
DisclosureSEC source: 0001193125-26-102708 · ownership.xml · nonDerivative · entry 1 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,864 F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:07 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 408 | $16.20 | $6,609.60 |
DisclosureSEC source: 0001193125-26-089439 · ownership.xml · nonDerivative · entry 1 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,348 F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024. Read SEC document |
| November 28, 2025 Filed Dec 3, 2025 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 229 | $21.12 | $4,836.48 |
DisclosureSEC source: 0001193125-25-305662 · ownership.xml · nonDerivative · entry 1 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,756 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on November 26, 2024. Read SEC document |
| September 03, 2025 Filed Sep 6, 2025 01:30 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-197422 · ownership.xml · nonDerivative · entry 2 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,985 F2 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 100% of the RSUs will vest on September 3, 2028, subject to the Reporting Person's continued service to the Company and only if certain performance criteria has been deemed achieved by the Compensation Committee of the Board. Read SEC document |
| September 03, 2025 Filed Sep 6, 2025 01:30 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 93,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-197422 · ownership.xml · nonDerivative · entry 1 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,985 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 50% of the RSUs will vest on September 3, 2026, and the remaining 50% will vest on September 3, 2027, subject to the Reporting Person's continued service to the Company. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Options (right to buy) · Derivative | 16,644 | $0.00 Strike: $99.69 | $0.00 |
DisclosureSEC source: 0000950170-25-037527 · ownership.xml · derivative · entry 3 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,644 Underlying: Common Stock · 16,644 shares Expires 2035-03-10 F3 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 8,276 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-037527 · ownership.xml · nonDerivative · entry 2 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,110 F2 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 491 | $100.13 | $49,163.83 |
DisclosureSEC source: 0000950170-25-037527 · ownership.xml · nonDerivative · entry 1 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,834 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 347 | $103.70 | $35,983.90 |
DisclosureSEC source: 0000950170-25-036693 · ownership.xml · nonDerivative · entry 2 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,847 F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 1,131 | $103.70 | $117,284.70 |
DisclosureSEC source: 0000950170-25-036693 · ownership.xml · nonDerivative · entry 1 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,194 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 6, 2023. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 296 | $101.34 | $29,996.64 |
DisclosureSEC source: 0000950170-25-035006 · ownership.xml · nonDerivative · entry 2 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,325 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 288 | $101.34 | $29,185.92 |
DisclosureSEC source: 0000950170-25-035006 · ownership.xml · nonDerivative · entry 1 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,037 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 391 | $103.77 | $40,574.07 |
DisclosureSEC source: 0000950170-25-032758 · ownership.xml · nonDerivative · entry 1 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,621 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024. F2 · balance_after: Amount of Securities Beneficially Owned includes 195 shares purchased under the Company's registered Employee Stock Purchase Plan on February 28, 2025. Read SEC document |
| November 26, 2024 Filed Nov 30, 2024 01:15 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $130.50 | $0.00 |
DisclosureSEC source: 0000950170-24-131938 · ownership.xml · derivative · entry 2 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2034-11-26 F2 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| November 26, 2024 Filed Nov 30, 2024 01:15 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-131938 · ownership.xml · nonDerivative · entry 1 Rothfuss Cristin · CIK 0002046214 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,817 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.